<DOC>
	<DOCNO>NCT02393898</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy frontline treatment ovarian cancer participant 70 year age old routine clinical practice Belgium . Bevacizumab use combination carboplatin/paclitaxel follow bevacizumab maintenance accordance Summary Product Characteristics ( SmPC ) .</brief_summary>
	<brief_title>BELOVA Data Collection : Safety Efficacy Frontline Bevacizumab Treatment Participants With Ovarian Cancer 70 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Aged 70 year old No treatment investigational agent within 28 day 2 halflives ( whichever longer ) prior enrollment Contraindications , warning , precaution bevacizumab</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>